Price Target Overview of CVS Health Corporation (NYSE:CVS)

Adjust Comment Print

The institutional investor held 714,708 shares of the medical and nursing services company at the end of 2017Q3, valued at $58.12M, up from 660,923 at the end of the previous reported quarter. Anadarko Pete Corp now has $31.25 billion valuation.

Over the last 5 days, CVS Health Corporation's shares returned 0.12% and in the past one month the figure appeared at -13.30%. APG Asset Management N.V. raised its stake in shares of CVS Health by 43.1% during the 4th quarter. It is down 0.00% since March 13, 2017 and is. It has outperformed by 14.45% the S&P500. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating, twelve have given a buy rating and two have issued a strong buy rating to the stock. Therefore 75% are positive. The stock price moved with change of -19.35% to its 50 Day low point and changed 1.53% comparing to its 50 Day high point. $98.31's average target is 3.57% above currents $94.92 stock price. Loop Capital reduced their price target on shares of CVS Health from $83.00 to $73.00 and set a "hold" rating on the stock in a research report on Tuesday, November 7th. The stock has "Hold" rating by KeyBanc Capital Markets on Thursday, October 26. Finally, ValuEngine lowered shares of CVS Health from a "buy" rating to a "hold" rating in a research note on Friday, February 2nd. Citigroup has "Neutral" rating and $87 target. The stock has "Buy" rating by Stifel Nicolaus on Monday, September 25. (NYSE:M) has "Hold" rating given on Thursday, November 12 by Evercore. KeyCorp maintained Kaman Corporation (NYSE:KAMN) on Friday, March 24 with "Equal Weight" rating. The firm has "Buy" rating by Jefferies given on Tuesday, August 23. The stock of Phillips 66 (NYSE:PSX) has "Buy" rating given on Tuesday, October 17 by Cowen & Co. The firm has "Hold" rating given on Thursday, January 4 by Robert W. Baird.

Investors sentiment increased to 1.01 in 2017 Q3. Its down 0.04, from 0.92 in 2017Q2. It is negative, as 60 investors sold CVS shares while 571 reduced holdings.

A number of other hedge funds have also added to or reduced their stakes in the business. The pharmacy operator reported $1.92 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $1.88 by $0.04. Fort Ltd Partnership holds 3.39% or 169,356 shares in its portfolio. Massachusetts Fincl Services Ma stated it has 0.65% of its portfolio in CVS Health Corporation (NYSE:CVS). Cleararc Inc, a Ohio-based fund reported 26,148 shares. New Vernon Invest Ltd Llc has 0.56% invested in CVS Health Corporation (NYSE:CVS) for 6,175 shares. Legal & General Group Plc now owns 5,587,303 shares of the pharmacy operator's stock worth $449,541,000 after acquiring an additional 281,632 shares in the last quarter. New Mexico Educational Retirement Board holds 94,687 shares or 0.37% of its portfolio. Harris LP has 0.34% invested in AutoNation, Inc. State Street invested 0.01% in AutoNation, Inc.

Since September 11, 2017, it had 0 insider purchases, and 6 selling transactions for $39.50 million activity. Covenant Multifamily Offices Ltd has 38,965 shares for 2.12% of their portfolio.

Teachers not backing down: Rally against pension bill brings hundreds to Frankfort
However, some state officials have pointed out that it could save taxpayers $3.2 billion over the next two decades. The raises would go back to 1.5 percent once the system is at least 90 percent funded, under the proposal.


CVS Health Corporation (CVS) reported fall change of -0.97% in last trading session. First PREMIER Bank grew its holdings in shares of CVS Health by 20.0% during the 4th quarter. It has underperformed by 35.60% the S&P500.

Analysts await Anadarko Petroleum Corporation (NYSE:APC) to report earnings on May, 1. Take a view on its long-term annual earnings per share (EPS) growth rate which is suggested by Analyst to reach at 7.66% for next 5 years and looking its past five year record, annual EPS growth rate was 16.40%. APC's profit will be $159.74M for 48.90 P/E if the $0.30 EPS becomes a reality. Their projections for the Next Quarter growth is 6.8 percent. The company has a market cap of $69.27 Billion.

PE ratio is one of the most widely used tools for stock selection. The Midstream segment gathers, processes, transports, and markets natural gas; transports, stores, fractionates, and markets natural gas liquids in the United States; and stores, refrigerates, and exports liquefied petroleum gas (LPG) primarily to Asia and Europe.

Investors sentiment decreased to 0.88 in Q3 2017. Its down 0.16, from 0.88 in 2017Q2. 34 funds opened positions while 73 raised stakes. Argi Investment Lc reported 11,803 shares stake. Schnieders Mngmt Ltd Limited Liability Company invested in 20,107 shares or 0.71% of the stock. Country Club Trust Na reported 0.92% stake. The correct version of this report can be read at https://www.thelincolnianonline.com/2018/03/07/kanawha-capital-management-llc-has-3-32-million-position-in-cvs-health-corp-cvs.html. The Indiana-based Spectrum Management Grp Inc has invested 0.12% in NVIDIA Corporation (NASDAQ:NVDA). Moreover, Peloton Wealth Strategists has 1.71% invested in CVS Health Corporation (NYSE:CVS) for 27,225 shares. Beck Mack Oliver Ltd Liability accumulated 13,781 shares. Carmignac Gestion accumulated 8.95M shares. Frontier Inv Co holds 245,006 shares. Rmb Capital Limited Liability Co stated it has 155,092 shares or 0.33% of all its holdings. 7,702 were reported by Da Davidson & Communication. Hightower Advsr Limited Liability, Illinois-based fund reported 245,981 shares. 0 analysts say it's a Hold while 0 analysts provided their expert opinion as Sell. Nvidia Corporation had 186 analyst reports since August 3, 2015 according to SRatingsIntel. On Friday, April 15 the stock rating was upgraded by JP Morgan to "Overweight". As per Wednesday, June 14, the company rating was maintained by Oppenheimer. Jefferies maintained it with "Buy" rating and $6200 target in Thursday, July 20 report. Leerink Swann set a $85.00 target price on CVS Health and gave the company a "buy" rating in a report on Monday, December 4th. The stock now has a consensus rating of "Buy" and an average target price of $87.03.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Comments